Skip to main content

Publications

What type of publication do you want to show?

2025

Type 2 Diabetes and associated Complications: Too little, too late?

Anson, M. (2025). Type 2 Diabetes and associated Complications: Too little, too late?. (University of Liverpool).

Thesis / Dissertation

2024

The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study.

Anson, M., Poon, J. S., Henney, A. E., Riley, D., Ibarbaru, G. H., Sieberhagen, C., . . . Hydes, T. (2024). The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study.. BMC medicine, 22(1), 574. doi:10.1186/s12916-024-03802-4

DOI
10.1186/s12916-024-03802-4
Journal article

Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD.

Henney, A. E., Riley, D. R., Hydes, T. J., Anson, M., Ibarburu, G. H., Zhao, S. S., . . . Alam, U. (2024). Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD.. Liver international : official journal of the International Association for the Study of the Liver. doi:10.1111/liv.16086

DOI
10.1111/liv.16086
Journal article

P1 The chemoprotective effect of anti-platelet agents on obesity-related cancer incidence in people with metabolic dysfunction associated steatotic liver disease

Anson, M., Poon, J. S., Henney, A., Riley, D., Ibarbaru, G., Sieberhagen, C., . . . Hydes, T. (2024). P1 The chemoprotective effect of anti-platelet agents on obesity-related cancer incidence in people with metabolic dysfunction associated steatotic liver disease. In P1 The chemoprotective effect of anti-platelet agents on obesity-related cancer incidence in people with metabolic dysfunction associated steatotic liver disease (pp. A11.2-A12). BMJ Publishing Group Ltd and British Society of Gastroenterology. doi:10.1136/gutjnl-2024-basl.14

DOI
10.1136/gutjnl-2024-basl.14
Conference Paper

Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data.

Henney, A. E., Riley, D. R., Heague, M., Hydes, T. J., Anson, M., Alam, U., & Cuthbertson, D. J. (2024). Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data.. Diabetes, obesity & metabolism, 26(10), 4665-4673. doi:10.1111/dom.15833

DOI
10.1111/dom.15833
Journal article

Aspirin and Ticagrelor Versus Aspirin and Clopidogrel or Prasugrel and the Effect on Staphylococcal-associated Infections: A Real-world Study.

Essa, H., Ding, W. Y., Rana, F., Zhao, S. S., Anson, M., Austin, P., . . . Alam, U. (2024). Aspirin and Ticagrelor Versus Aspirin and Clopidogrel or Prasugrel and the Effect on Staphylococcal-associated Infections: A Real-world Study.. Clinical therapeutics, 46(9), 689-695. doi:10.1016/j.clinthera.2024.07.001

DOI
10.1016/j.clinthera.2024.07.001
Journal article

Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.

Anson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., . . . Alam, U. (2024). Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.. EClinicalMedicine, 75, 102777. doi:10.1016/j.eclinm.2024.102777

DOI
10.1016/j.eclinm.2024.102777
Journal article

SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum

Preston, F. G., Anson, M., Riley, D. R., Ibarburu, G. H., Henney, A., Lip, G. Y. H., . . . Zhao, S. S. (2024). SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum. Clinical Therapeutics. doi:10.1016/j.clinthera.2024.06.021

DOI
10.1016/j.clinthera.2024.06.021
Journal article

Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.

Anson, M., Henney, A. E., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., Cuthbertson, D. J., . . . Alam, U. (2024). Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.. Diabetes, obesity & metabolism, 26(7), 2606-2623. doi:10.1111/dom.15576

DOI
10.1111/dom.15576
Journal article

Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis.

Henney, A. E., Riley, D. R., O'Connor, B., Hydes, T. J., Anson, M., Zhao, S. S., . . . Cuthbertson, D. J. (2024). Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis.. Diabetes, obesity & metabolism. doi:10.1111/dom.15708

DOI
10.1111/dom.15708
Journal article

Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis.

Lai, J. Y. M., Riley, D. R., Anson, M., Henney, A., Cuthbertson, D. J., Hernadez, G., . . . Alam, U. (2024). Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(4), 833-842. doi:10.1007/s13300-024-01544-3

DOI
10.1007/s13300-024-01544-3
Journal article

2023

Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity.

Anson, M., Zhao, S. S., Essa, H., Austin, P., Ibarburu, G. H., Lip, G. Y. H., & Alam, U. (2023). Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity.. Clinical therapeutics, 45(12), 1259-1265. doi:10.1016/j.clinthera.2023.07.026

DOI
10.1016/j.clinthera.2023.07.026
Journal article

Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers

Lim, J. Z. M., Burgess, J., Ooi, C., Ferdousi, M., Azmi, S., Kalteniece, A., . . . Alam, U. (2023). Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers. DIAGNOSTICS, 13(17). doi:10.3390/diagnostics13172793

DOI
10.3390/diagnostics13172793
Journal article

2022

2020